Skip to content

한국오가논 – Organon Korea logo

Main menu
    • 한국오가논
    • Our Stories
      • 비전·가치·미션
      • 다양성·형평성·포용성
    • 경영진
    • ESG
    • 기업정책
    • 핵심사업
    • 제품리스트
  • 전문의 자료
    • 보도자료
    • 공지사항
  • 인재영입
  • 여성건강 VOICE

고객문의

제품리스트

Visit Organon's LinkedIn Opens a new window Visit Organon's Instagram Opens a new window Visit Organon's YouTube Opens a new window

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:
한국오가논 - Organon Korea » About Us » Leadership » Bio_leadership

김소은

한국오가논 대표

Director since
2021

김소은 대표는 2021년 출범한 글로벌 헬스케어 기업인 오가논의 한국법인 초대 대표를 역임하고 있습니다. 한국 MSD에서 대외협력(External Affairs) 리드 역할을 수행하며 동시에 한국오가논이 한국MSD로부터 분사하는 과정에서 트랜지션 리드(Transition Lead)를 맡아 기업 분사 과정을 총괄한 바 있습니다.   

김 대표는 1998년 한국MSD에 입사 후 영업 및 마케팅, 커머셜 오퍼레이션(Commercial Operations), 대외협력(Market Access, Communication, Policy) 분야를 비롯해 아시아 태평양 지역에 이르기까지 다양한 지역과 조직에서 비즈니스 성과를 내며 폭넓은 경험을 쌓아왔습니다. 사업 부문으로는 프라이머리 케어(Primary Care) 사업부를 총괄하며, 당뇨병·심혈관 분야 사업을 성공적으로 이끌었고 국내 기업과의 핵심 사업 제휴, 디지털 전략 구축 등 성과를 이루었습니다. 또한, 이에 앞서 커머셜 오퍼레이션(Commercial Operations) 부문을 이끌며 조직 역량 강화를 주도했으며, 아시아 태평양 지역 MSE(Marketing and Sales Excellence) 이사로 선임되어 마케팅과 영업 및 전반의 전략적 접근과 생산성 향상을 리드했습니다.  

고려대학교 식품 공학 학사, 영국 셰필드핼럼대학교(Sheffield Hallam University) 식품 경영학 석사 학위를 취득했으며, 하버드 경영대학원의 MSD 이머징마켓 경영자 리더십 프로그램을 수료하였습니다.

Connect with us on social

Linkedin icon Opens a new window Instagram icon Opens a new window YouTube icon Opens a new window
한국오가논 – Organon Korea logo

Company

  • 한국오가논

Resources

  • 보도자료
  • 전문의 자료

Contact us

  • 고객문의
  • 글로벌 사업장
  • Forward-Looking Statement
  • Cookie Policy
  • 개인정보처리방침
  • Term of Use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept